Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753506 · ClinicalTrials.gov registry record · NA
Artemisinin to Reduce The Symptoms of Schizophrenia
A NA study, sponsored by Sheppard Pratt Health System.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT00753506: Completed NA study, sponsored by Sheppard Pratt Health System.
NCT00753506 is a NA study that has completed, run by Sheppard Pratt Health System. The registered enrollment target is 66 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00753506, a NA study, has completed, sponsored by Sheppard Pratt Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.
Primary Outcome
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale. PAN
Interventions
- DIETARY_SUPPLEMENT Artemisinin
- DIETARY_SUPPLEMENT Identical looking placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | NA |
What the finished NCT00753506 record still lists
NCT00753506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Artemisinin is the first listed.
NCT00753506 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00753506 about?
NCT00753506 is a clinical study titled "Artemisinin to Reduce The Symptoms of Schizophrenia". The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.
What is the current status of trial NCT00753506?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2008-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00753506?
The interventions under investigation include: Artemisinin (DIETARY_SUPPLEMENT), Identical looking placebo capsule (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00753506?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00753506's enrollment target sits among peer trials
66 1139th of 2000 higher than 857 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia